Skip to content
eHealthTutorial — Research Peptide Reviews
Investigational • Not FDA-approved

Ghrelin-receptor secretagogue research

Ipamorelin

Ipamorelin is a synthetic growth-hormone secretagogue studied in human pharmacology and a postoperative-ileus trial. A hormone response is not evidence of body-composition benefit.

Open calculator Explore the research
Generic research visual — not a commercial product
Compound typeSynthetic pentapeptide secretagogue
Evidence baseHuman pharmacology and controlled clinical trial
Regulatory contextInvestigational / Not FDA-approved
Page purposeResearch and calculation

Compound calculator

Ipamorelin reconstitution calculator

Enter the values printed on your vial and the liquid volume you added to calculate concentration, liquid volume, and the corresponding mark on a U-100 syringe scale.

Selected peptide or compoundIpamorelin
Enter the total amount printed on the vial.
mL
Enter the liquid volume added in milliliters.
You provide this amount; the calculator does not select or recommend it.
Scale reference only; confirm the markings on the physical syringe.

Your Ipamorelin calculation appears here

Enter the three required values to see the mathematical result.

This calculator performs arithmetic using values you enter. It does not select or recommend an amount, schedule, treatment, preparation method, or method of administration.

Research overview

What is Ipamorelin?

Ipamorelin is a short ghrelin-receptor agonist designed to stimulate growth-hormone release. It is different from CJC-1295, which is a growth-hormone-releasing-hormone analogue. The studies below tested ipamorelin alone in defined settings and do not validate a combination sold by a supplier.

What has research examined?

A human-volunteer study modeled pharmacokinetic and growth-hormone concentration responses after studied ipamorelin exposure. A later multicenter randomized, placebo-controlled proof-of-concept study evaluated a distinct clinical endpoint: postoperative bowel recovery after resection. The clinical trial did not demonstrate a convincing primary-endpoint benefit. FDA flags potential peptide aggregation/impurity and immunogenicity risks for proposed compounded ipamorelin acetate and notes serious adverse events, including death, in the intravenous gastric-motility study without established causality.

Important limitation

Neither a GH biomarker response nor a clinical trial for ileus demonstrates muscle gain or safe unsupervised use. FDA says safety information for other proposed injectable routes is insufficient; a supplier’s vial is not equivalent to the studied product. This page gives no amount or use instruction.

Research references

Calculation boundary

The calculator performs concentration arithmetic only when a user enters a mass and liquid volume. It does not verify identity, formulation, purity, sterility, stability, compatibility, biological-unit equivalence, or whether reconstitution applies to a particular product. Do not convert IU or other biological units to mg without an authoritative, exact-product relationship.

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.